Coverage from the National Community Oncology Dispensing Association Spring Forum 2018.
Direct and indirect remuneration (DIR) fees have been a growing concern for community pharmacists, and pharmacists who haven’t had an issue with them yet will run into them soon, said Representative Doug Collins, R-Georgia, who was the keynote speaker at the National Community Oncology Dispensing Association Spring Forum 2018, held March 1-3 in Dallas, Texas.
Collins focused his discussion on DIR fees and how they are increasing costs for the patient—by pushing them into the donut hole and catastrophic coverage in Medicare—and for the healthcare system. In addition, since Medicare patients are being pushed into catastrophic coverage, CMS has to pick up the extra costs, which means the taxpayer is spending more.
In general, DIR fees to pharmacy benefit managers (PBMs) are driving up costs, and Collins said research has found that the average community pharmacist loses $83,000 a year on DIR fees alone. The problem is that the industry is on track for a situation where PBMs begin to either kill off community pharmacies or they buy other PBMs and consolidate even further.
That said, Collins thinks PBMs can be used for good.
“I don’t hate PBMs; I hate the way they do business now,” he explained. “When they started, they actually were a good idea. They actually were designed to lower costs, to provide better interactions to get drugs.”
The problem is the use of strategies like DIR fees. The Office of the Inspector General has documented significant spending increases in Medicare Part D for catastrophic coverage and an increased number of people getting pushed into the catastrophic range.
“The increase actually coincides with—guess what?—DIR fees,” he said. “It’s almost identical. When DIR fees started going up, we started seeing the catastrophic coverage of CMS go up.”
The report found that from 2010 to 2015, the costs paid by Medicare increased from $10 billion to $33 billion in 5 years. And since 2015, those costs have gone up even more, Collins added.
Collins also touched upon the ongoing healthcare debate in Washington, DC, discussing the Affordable Care Act (ACA) and said that Congress “failed America last year” when it was unable to pass legislation repealing and replacing the ACA. Parts of the health law are things he agrees with—provisions like coverage for preexisting conditions and the ban on lifetime limits—but he believes those changes could have been made without overhauling the whole healthcare system. Unfortunately, he doesn’t see a way to move forward at this point to try to make any further changes to the ACA.
“As we move forward in this, this year, frankly, I wouldn’t expect to see a great deal,” Collins admitted. “It happens to be one of those election years.”
Results Show Strong Responses for Brentuximab Vedotin Plus Nivolumab Combo in Patients With cHL
December 11th 2023Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So
December 11th 2023Presenters at the American Society of Hematology Annual Meeting and Exposition agreed that novel strategies, such as CRISPR and base editing, have potential to fine-tune the latest immunotherapy advancements to increase the efficacy and durability of a range of treatments.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Cellular Therapies in Lymphoma Bring Hope, but Optimizing Their Use Remains a Challenge
December 10th 2023Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.
Read More